Company / Cost of Revenue
NovoCure Ltd Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$166.9M
FY2025
5-year range
$114.9M / $166.9M
FY2021-FY2025
Trend
+21.6%
vs FY2024
Sector context
#77 of 107
Health Care
What the data says
At $167M, NovoCure Ltd's cost of revenue ranks #31 of 107 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $115M in FY2022 to $167M in FY2025.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of +9.4%.
Increased from $128M to $167M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +13.3%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
#31 of 107 in Health CareTop 28% of 107This company $166.9M Sector average $11.8B
▼
-98.6% below sector average
Key checks
Key Insights
- NovoCure Ltd's cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, cost of revenue increased 21.6% year-over-year.
- Ranks #77 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $166.9M | +21.6% |
| FY2024 | $137.2M | +6.9% |
| FY2023 | $128.3M | +11.7% |
| FY2022 | $114.9M | -0.0% |
| FY2021 | $114.9M | +7.9% |
| FY2020 | $106.5M | +20.2% |
| FY2019 | $88.6M | +10.7% |
| FY2018 | $80.0M | +43.9% |
| FY2017 | $55.6M | +39.5% |
| FY2016 | $39.9M | +93.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026